SCHEMBL29436247

SCHEMBL29436247

CCNC(=O)Cn1nc(-c2ccc(OCCC(F)(F)F)nc2)ccc1=O

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.49
▸ KDM4E B2RXH2 5/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ USP2 O75604 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ TP53 P04637 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ CYP2D6 P10635 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23495281 1.00 POLB (0.49) POLBKDM4EALDH1A1HSD17B10USP2
SCHEMBL23495393 0.90 CYP1A2 (0.51) POLBKDM4EALDH1A1HSD17B10USP2
SCHEMBL29436184 0.90 CYP1A2 (0.51) POLBKDM4EALDH1A1HSD17B10USP2
SCHEMBL26290814 0.89 POLB (0.53) POLBKDM4EALDH1A1HSD17B10USP2
SCHEMBL23495413 0.87 KDM4E (0.58) POLBKDM4EALDH1A1HSD17B10USP2
SCHEMBL23495128 0.87 POLB (0.49) POLBKDM4EALDH1A1HSD17B10USP2
SCHEMBL29436159 0.87 POLB (0.49) POLBKDM4EALDH1A1HSD17B10USP2
SCHEMBL23495133 0.86 KDM4E (0.57) POLBKDM4EALDH1A1HSD17B10USP2
SCHEMBL23495270 0.83 POLB (0.49) POLBKDM4EALDH1A1HSD17B10USP2
SCHEMBL23495245 0.82 MEN1 (0.53) POLBKDM4EALDH1A1HSD17B10USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340526-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2025-11-06 — — US disclosed
US-12415794-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-09-16 — — US disclosed
EP-4248972-A2 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2023-09-27 — — EP disclosed
US-20230293518-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. 2023-09-21 — — US disclosed
EP-4149465-A1 SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. (US) 2023-03-22 — — EP disclosed
US-20220081410-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2022-03-17 — — US disclosed
US-11236065-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPECUTICS, INC. (US) 2022-02-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230293518-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES IL6, MUSK, SMN1; SMN2 POLB 1354/4885KDM4E 3081/4885ALDH1A1 308/4885
US-20220081410-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A POLB 1519/4885KDM4E 3514/4885ALDH1A1 270/4885
US-12415794-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A POLB 1519/4885KDM4E 3514/4885ALDH1A1 270/4885
US-11236065-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A POLB 1519/4885KDM4E 3514/4885ALDH1A1 270/4885
US-20250340526-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A POLB 1519/4885KDM4E 3514/4885ALDH1A1 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback